Hib conjugate vaccine - Masoondarou BiopharmaAlternative Names: MAS-HibVAC
Latest Information Update: 03 Mar 2014
At a glance
- Originator Masoondarou Biopharma
- Class Haemophilus vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemophilus infections
Most Recent Events
- 01 Apr 2013 Launched for Haemophilus infections in Iran (IM)
- 20 Apr 2012 Phase-III clinical trials in Haemophilus infections in Iran (IM)